Hong Kong's new drug regulator, the Centre for Medical Products Regulation (CMPR), aims to build an internationally trusted agency that fosters medical innovation. Controller Li Zili stated the CMPR will focus on primary evaluation of drugs and devices, leveraging Hong Kong's unique position to serve both local and global patients. The goal is to accelerate clinical application and promote reforms, with a focus on rare diseases and advanced therapies.
The establishment of the CMPR aims to accelerate the approval and availability of new drugs and medical devices in Hong Kong and globally, potentially reducing patient costs and improving access to innovative treatments, particularly for rare diseases.
Hong Kong is set to establish a new regulatory authority for medical products, the Centre for Medical Products Regulation (CMPR), by the end of 2026. Li Zili, appointed as its controller, has pledged to build a globally trusted agency that will act as a catalyst for medical innovation. The CMPR aims to protect public health and promote innovation by focusing on the primary evaluation of drugs and medical devices, thereby accelerating their clinical application. Li emphasized leveraging Hong Kong's unique strategic position to serve patients both locally and worldwide. The center will also focus on exploring development in areas such as rare diseases and advanced therapies, and will establish an interdisciplinary scientific team to enhance international cooperation. Experts have urged the new agency to prioritize rare disease drug approvals and recruit international talent to expedite reviews.
Pick the topics you care about. Get only what matters, on your cadence.